SEHK:9995Biotechs
RemeGen (SEHK:9995) Is Up 30.0% After New HER2-Low Breast Cancer Approval Has The Bull Case Changed?
RemeGen Co., Ltd. recently received approval from China’s National Medical Products Administration for a fourth indication of its antibody-drug conjugate Disitamab Vedotin, now authorized to treat adult patients with unresectable or metastatic HER2-low expressing breast cancer with liver metastases after prior systemic therapy or early recurrence post-adjuvant chemotherapy.
The new indication expands Disitamab Vedotin’s role across gastric, urothelial, HER2-positive, and now HER2-low breast...